SELLAS Life Sciences Group, Inc.

NasdaqCM:SLS 주식 보고서

시가총액: US$76.6m

SELLAS Life Sciences Group 과거 수익 실적

과거 기준 확인 0/6

SELLAS Life Sciences Group's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 12.2% per year.

주요 정보

-9.7%

수익 성장률

77.7%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률-12.2%
자기자본 수익률-1,182.3%
순이익n/a
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jun 18
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jul 13
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Sep 20
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

Aug 09

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Mar 08
We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Nov 23
Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth

Jul 19
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth

SELLAS Life Sciences updates on at-the-market offering

Jun 02

SELLAS Life Sciences jumps 43% after Reddit mentions

Feb 03

수익 및 비용 분석

SELLAS Life Sciences Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqCM:SLS 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 240-341421
31 Mar 240-361422
31 Dec 230-371424
30 Sep 230-381425
30 Jun 230-361423
31 Mar 230-361423
31 Dec 221-411320
30 Sep 221-391218
30 Jun 221-391118
31 Mar 223-351116
31 Dec 218-211116
30 Sep 2110-181215
30 Jun 2110-151213
31 Mar 218-151112
31 Dec 202-17109
30 Sep 200-2199
30 Jun 200-2898
31 Mar 200-27107
31 Dec 190-28107
30 Sep 190-34119
30 Jun 190-32109
31 Mar 190-36129
31 Dec 180-41139
30 Sep 180-37106
30 Jun 180-32125
31 Mar 180-30116
31 Dec 170-2496
30 Sep 170-21119
30 Jun 170-231012
31 Mar 170-20612
31 Dec 160-18511

양질의 수익: SLS is currently unprofitable.

이익 마진 증가: SLS is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: SLS is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.

성장 가속화: Unable to compare SLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: SLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


자기자본 수익률

높은 ROE: SLS has a negative Return on Equity (-1182.25%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기